000106614 001__ 106614
000106614 005__ 20210902121839.0
000106614 0247_ $$2doi$$a10.1021/acs.molpharmaceut.0c00408
000106614 0248_ $$2sideral$$a120398
000106614 037__ $$aART-2020-120398
000106614 041__ $$aeng
000106614 100__ $$0(orcid)0000-0002-1505-498X$$aYus, C.$$uUniversidad de Zaragoza
000106614 245__ $$aControlling Particle Size and Release Kinetics in the Sustained Delivery of Oral Antibiotics Using pH-Independent Mucoadhesive Polymers
000106614 260__ $$c2020
000106614 5060_ $$aAccess copy available to the general public$$fUnrestricted
000106614 5203_ $$aCopolymers synthesized from acrylic acid and methacrylic acid used as gastroprotective and mucoadhesive enteric coatings have been used to prepare micro- (~2 µm), submicro- (~200 nm), and nanoparticles (~20 nm) containing rifampicin (Rif) to obtain time-controlled drug release kinetics. Different particle sizes and drug release kinetics have been obtained using different synthesis conditions and fabrication techniques including the use of an electrosprayer and an interdigital microfabricated micromixer. The antimicrobial action of the encapsulated Rif has been demonstrated against Staphylococcus aureus ATCC 25923 and compared with the effect of the equivalent dose of the free macrolide antibiotic. At low concentrations, the encapsulated antibiotic showed superior antimicrobial activity than the free drug. The stability of the developed particles has been evaluated in vitro under simulated gastric and intestinal conditions. At the concentrations tested, a reduced cytotoxicity against different human cell lines was observed after analyzing their subcytotoxic doses and the influence on their cell cycle by flow cytometry. Drug release kinetics can be tuned by adjusting particle sizes, and it would be possible to reach the minimum inhibitory concentration or the minimum bactericidal concentration at different time points depending on the medical needs.
000106614 536__ $$9info:eu-repo/grantAgreement/EC/FP7/614715/EU/A Photo-triggered On-demand Drug Delivery System for Chronic Pain/NANOHEDONISM$$9info:eu-repo/grantAgreement/ES/MCIU/RTI2018-099019-A-I00$$9info:eu-repo/grantAgreement/ES/MINECO/CTQ2017-84473-R
000106614 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000106614 590__ $$a4.939$$b2020
000106614 591__ $$aPHARMACOLOGY & PHARMACY$$b69 / 275 = 0.251$$c2020$$dQ2$$eT1
000106614 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b51 / 140 = 0.364$$c2020$$dQ2$$eT2
000106614 592__ $$a1.129$$b2020
000106614 593__ $$aDrug Discovery$$c2020$$dQ1
000106614 593__ $$aPharmaceutical Science$$c2020$$dQ1
000106614 593__ $$aMolecular Medicine$$c2020$$dQ1
000106614 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000106614 700__ $$0(orcid)0000-0002-2966-9088$$aIrusta, S.$$uUniversidad de Zaragoza
000106614 700__ $$0(orcid)0000-0002-6873-5244$$aSebastian, V.$$uUniversidad de Zaragoza
000106614 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, M.$$uUniversidad de Zaragoza
000106614 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000106614 7102_ $$15005$$2790$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Tecnologi. Medio Ambiente
000106614 773__ $$g17, 9 (2020), 3314-3327$$pMol. pharm.$$tMolecular pharmaceutics$$x1543-8384
000106614 8564_ $$s743513$$uhttps://zaguan.unizar.es/record/106614/files/texto_completo.pdf$$yPostprint
000106614 8564_ $$s2452402$$uhttps://zaguan.unizar.es/record/106614/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000106614 909CO $$ooai:zaguan.unizar.es:106614$$particulos$$pdriver
000106614 951__ $$a2021-09-02-10:22:09
000106614 980__ $$aARTICLE